177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

NCT05496959 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

93

Enrollment

OTHER

Sponsor class

Conditions

Oligometastatic Prostate Carcinoma
Prostate Adenocarcinoma
Recurrent Prostate Adenocarcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions

DRUG: Lutetium Lu-177 PNT2002
OTHER: Quality-of-Life Assessment
RADIATION: Stereotactic Body Radiation Therapy

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]